CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.
CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.
复制标题
DOI：
10.5045/br.2013.48.2.121
复制
发表时间：
2013-06
期刊：
影响因子：
2.2
通讯作者：
Bedewy A
中科院分区：
文献类型：
--
作者：
Bedewy M;El-Maghraby S;Bedewy A
对霍奇金淋巴瘤(HL)的认识进展表明，免疫细胞和细胞因子的多种功能与临床转归有关。CD163和c-Met的表达被认为在淋巴系统恶性肿瘤中起一定作用。因此，我们研究了CD163、c-Met和血清游离轻链(SFLC)的表达与晚期经典型HL(CHL)患者临床病理特征的关系。采用免疫组织化学方法检测34例慢性淋巴细胞性白血病(CHL)患者淋巴结活检组织中CD163和c-Met的表达，并用双抗体夹心法测定治疗前sFLC水平。CD163的高表达与年龄、B症状、国际预后评分≥3、混合细胞亚型和治疗反应低相关。此外，c-Met的高表达与确诊年龄的增加、白细胞增多、B症状以及获得完全缓解的机会较低相关。SFLC水平与确诊年龄增加、淋巴细胞减少、IPS≥3、B症状和较低的完全缓解率相关。在晚期慢性粒细胞白血病中，CD163和c-Met的高表达与不良的预后参数和治疗反应差显著相关。治疗前高sFLC水平也与不良危险因素相关，提示可将其作为候选预后标志物。一种综合的预后标记物的方法可能代表着朝着开发针对HL的量身定制的治疗方法迈出了一步。
Advances in the understanding of Hodgkin's lymphoma (HL) show various functions of infiltrating immune cells and cytokines in relation to clinical outcomes. The expression of CD163 and c-Met has been suggested to have a role in lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and serum free light chain (sFLC) in relation to the clinicopathological features of patients with advanced classical HL (cHL). We assessed the expression of CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph node biopsy sections and the levels of pretreatment sFLC were estimated using ELISA. High CD163 expression correlated with increased age, B symptoms, International Prognostic Score (IPS) ≥3, mixed cellularity subtype, and low response to treatment. Further, high c-Met expression correlated with increased age at diagnosis, leukocytosis, B symptoms, and lower chance to achieve complete remission. The sFLC levels correlated with increased age at diagnosis, lymphopenia, IPS ≥3, B symptoms, and lower complete remission rates. In advanced cHL, increased expression of CD163 and c-Met showed a significant association with adverse prognostic parameters and poor response to treatment. Pretreatment high sFLC level also correlated with poor risk factors, suggesting its use as a candidate prognostic marker. A comprehensive approach for prognostic markers might represent a step towards developing a tailored therapeutic approach for HL.